Duke’s brain tumor program was one of the earliest in the country, founded in 1937. Today, the Preston Robert Tisch Brain Tumor Center at Duke sees approximately 900 new adult brain tumor patients and 75 new pediatric brain tumor patients per year from across the country and around the world.
Patients come to Duke for the most advanced treatments – often therapies that are not available anywhere else. Duke’s brain cancer specialists are recognized leaders in brain cancer who co-developed a vaccine that extends the lives of people with glioblastoma, an aggressive type of brain tumor. Research continues to make the vaccine stronger and the immune response more powerful.
Read the latest in the Duke Neurosurgery Annual Report: The Brain Tumor Center
Leaders of the center are internationally recognized physician scientists who have many decades of experience studying and treating brain and spinal cord tumors:
- David Ashley, MBBS, FRACP, PhD, Director
- Allan Friedman, MD, Deputy Director
- Henry Friedman, MD, Deputy Director
- Peter Fecci, MD, PhD, Associate Deputy Director
Brain and Spine Tumor Faculty
- Darell Bigner, MD, PhD
- Vidyalakshmi Chandramohan, PhD
- Patrick Codd, MD
- Steven Cook, MD
- Annick Desjardins, MD
- Rory Goodwin, MD, PhD
- Gerald Grant, MD
- Matthias Gromeier, MD
- Margaret Johnson, MD
- Steven Keir, PhD
- Mustafa Khasraw, MD
- Jordan Komisarow, MD
- Justin Low, MD, PhD
- Quinn Ostrom, PhD
- Anoop Patel, MD
- Katherine Peters, MD, PhD
- Madison Shoaf, MD
- Matthew Waitkus, MD, PhD
- Kyle Walsh, PhD
- Gao Zhang, PhD